GlassScriptPhysician profile
Howard M Sklarek
NPI 1336229558
$3,927.00
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $336 · 2021: $389 · 2022: $886 · 2023: $1,115 · 2024: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,237.76 | 2019-2024 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $799.44 | 2019-2024 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.43 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Genentech USA, INC. | $162.36 | 2019-2020 | |
| Grifols USA, LLC | $162.16 | 2022-2024 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $156.12 | 2019-2024 | Dupixent |
| Amgen INC. | $155.31 | 2021-2024 | Tezspire, Otezla, Repatha |
| Electromed, INC. | $153.08 | 2022-2024 | Smartvest |
| Genzyme Corporation | $147.07 | 2019-2024 | |
| Fisher & Paykel Healthcare INC | $126.07 | 2023 | Fisher & Paykel Healthcare |
| Baxter Healthcare | $122.37 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Metaneb System |
| Merck Sharp & Dohme LLC | $114.94 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Novartis Pharmaceuticals Corporation | $46.98 | 2019-2022 | |
| Daiichi Sankyo INC. | $39.37 | 2019-2020 | |
| Inspire Medical Systems, INC. | $31.84 | 2023 | Inspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $22.00 | 2019 | |
| Alkermes, INC. | $21.72 | 2019 | |
| Abbvie INC. | $21.11 | 2023 | Teflaro |
| Actelion Pharmaceuticals US, INC. | $20.41 | 2019 | |
| Novo Nordisk INC | $19.61 | 2019 | |
| Allergan, INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Sklarek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.